ASH 2024 – AstraZeneca aims to fix Calquence’s position
But with Brukinsa and degraders looming, will fixed dosing make the difference?
ASH 2024 – Jaypirca's confirmation, despite no survival
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
ASH 2024 preview – more challenges to the BTK order
First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
EHA 2024 – Nurix and BeiGene’s degraders shine
NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.
A Calquence win seven years in the making
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
